PDS Biotechnology Corp: management transactions · United States · SEC (Form 4)

About PDS Biotechnology Corp

PDS Biotechnology Corp. is a U.S.-listed biopharmaceutical company trading on the Nasdaq in the United States. Headquartered in Princeton, New Jersey, the company is focused on oncology immunotherapy, with a strategy built around proprietary technologies designed to stimulate T cells and reshape the tumor microenvironment. Over time, PDS Biotech has evolved from an early Versamune®-centered platform story into a broader late-stage immunotherapy pipeline, with PDS01ADC now forming a second core pillar of its development strategy. The company positions itself as a late-stage immunotherapy developer seeking to change how the immune system targets and kills cancer cells. Its business is primarily research and development, not commercial sales. The lead program is PDS0101, also referred to as Versamune® HPV, which is being developed mainly for HPV-associated cancers, especially recurrent/metastatic head and neck squamous cell carcinoma. A second major asset is PDS01ADC, a tumor-targeted IL-12 immunocytokine, which is being evaluated in metastatic colorectal cancer and advanced castration-resistant prostate cancer. The broader pipeline also includes additional Versamune®-based combination approaches, with the company emphasizing synergy with immune checkpoint inhibitors. In competitive terms, PDS Biotech is a small, clinical-stage oncology biotech operating in a crowded immuno-oncology landscape dominated by much larger pharmaceutical companies. Its differentiation lies in its platform science, the mechanistic rationale behind its combinations, and the possibility of generating durable responses in difficult-to-treat solid tumors. As with most development-stage biotech companies, however, the investment case depends heavily on clinical data, regulatory milestones, and access to capital rather than current revenue generation. Recent developments underline both progress and execution risk. In 2026, PDS Biotech reported clinical and corporate updates across its pipeline, including progress in the VERSATILE-003 Phase 3 program and continued advancement of PDS01ADC. The company also highlighted recent positive clinical and biomarker data in metastatic colorectal cancer and additional conference presentations in prostate cancer. Financing activity has also been part of the story, reflecting the capital-intensive nature of oncology drug development. For investors in French-speaking markets, PDSB represents a high-risk, high-upside Nasdaq biotech profile in the United States, with value tied mainly to pipeline execution and future clinical readouts.